Moleculin Biotech Inc (MBRX)

[king oil]

Moleculin Biotech (MBRX) Signs Agreement With First Hospital For Annamycin Trials

HOUSTON, TX--(Marketwired - October 03, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into an agreement to conduct its clinical trial to study Annamycin for the treatment of acute myeloid leukemia (AML) with the first of several hospitals desiring to be treatment centers.

"Now that our IND (investigational new drug) application is approved, the race is on to open treatment centers and begin recruiting patients," commented Walter Klemp, Chairman and CEO of Moleculin. "We have identified 14 treatment sites that meet our criteria and have expressed an interest in participating, so there will be much more of this to come."

"This first facility is a hematology clinic in a major hospital in Poland," continued Mr. Klemp. "Because of the difference in process in Poland compared with the US, we were able to get this site signed up very shortly following the approval of our IND. We anticipate announcing additional sites over the coming months."

Moleculin entered into this first agreement with a hospital in Poznan, Poland (Hospital of the Transfiguration of the Lord -- Medical University in Poznan, Department of Hematology and Marrow Transplantation). The ability to treat patients in this and other Polish sites will require a separate regulatory approval in Poland based on the approved US IND. This is one of seven planned treatment sites in Poland.


https://www.biospace.com/News/moleculin-biotech-signs-agreement-with-first/471321/source=MoreNews